cagrisema cagrilintide semaglutide phase 3 results 2024 2025 After blow, Novo reveals data for obesity 'triple' Presenters to provide first look
Presenters to provide first look at data from REIMAGINE trials of cagrilintide semaglutide for type 2 diabetes management ADA Meeting News Amylin Commands Weight Loss Attention as Industry Anticipates Novo's Phase III CagriSema Readout BioSpace Novo Nordisk's CagriSema trial deals blow in obesity drug battle with Eli Lilly Reuters ECO 2026 Assessing Cardiovascular Safety and Outcomes With the Combination of Cagrilintide and Semaglutide (CagriSema): REDEFINE 3 Randomised Clinical Trial Baseline Characteristics and Methods
Novo Nordisk's CagriSema 2.4 mg 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026
Pay in 4 interest-free payments of $6.91 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22



